Incyte (INCY) Deferred Taxes (2021 - 2026)
Incyte posted quarterly Deferred Taxes of $63.4 million for Q1 2026, up 1045.66% year-on-year from $5.5 million in Q1 2025, and up 569.85% on a QoQ basis from -$13.5 million in Q4 2025.
Incyte (INCY) has 6 years of Deferred Taxes data on file, last reported at $63.4 million in Q1 2026.
- For the quarter ending Q1 2026, Deferred Taxes rose 1045.66% year-over-year to $63.4 million; the trailing twelve-month figure through Mar 2026 stood at -$177.6 million (down 498.16% YoY), and the FY2025 full-year result was -$247.7 million, down 389.51% from the prior year.
- Deferred Taxes for Q1 2026 stood at $63.4 million, up from -$13.5 million in the prior quarter.
- Across five years, Deferred Taxes topped out at $66.0 million in Q4 2023 and bottomed at -$124.1 million in Q3 2025.
- The 5-year median for Deferred Taxes is -$56000.0 (2024), against an average of $181823.5.
- The widest annual swing landed in 2022, when Deferred Taxes plunged 44305.56%; it then jumped 1152.37% in 2023.
- A 5-year view of Deferred Taxes shows it stood at -$16.7 million in 2022, then jumped by 496.06% to $66.0 million in 2023, then plunged by 100.08% to -$56000.0 in 2024, then slumped by 24001.79% to -$13.5 million in 2025, then soared by 569.85% to $63.4 million in 2026.
- The last three Deferred Taxes figures came in at $63.4 million (Q1 2026), -$13.5 million (Q4 2025), and -$124.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -65.30 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 96.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 9.31 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 63.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.42 Mn |
| Dec 31, 2025 | -13.50 Mn |
| Sep 30, 2025 | -124.12 Mn |
| Jun 30, 2025 | -103.37 Mn |
| Mar 31, 2025 | -6.71 Mn |
| Dec 31, 2024 | -56,000.00 |
| Sep 30, 2024 | 33.88 Mn |
| Jun 30, 2024 | 17.48 Mn |
| Mar 31, 2024 | 34.25 Mn |
| Dec 31, 2023 | 65.98 Mn |
| Sep 30, 2023 | 31.06 Mn |
| Jun 30, 2023 | 39.70 Mn |
| Mar 31, 2023 | 22.16 Mn |
| Dec 31, 2022 | -16.66 Mn |
| Sep 30, 2022 | -7.96 Mn |
| Jun 30, 2022 | -30.37 Mn |
| Mar 31, 2022 | -2.11 Mn |
| Dec 31, 2021 | 465.43 Mn |
| Sep 30, 2021 | 18,000.00 |
| Jun 30, 2021 | 230,000.00 |
| Mar 31, 2021 | -70,000.00 |